Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Predictive biomarkers in bladder & kidney cancer: insights into recent progress

Srikala Sridhar • 30 May 2026
ASCO 2026
Bladder Cancer Genitourinary Cancer Kidney Cancer

Srikala Sridhar, MD, Princess Margaret Cancer Centre, Toronto, Canada, discusses advancements in identifying reliable predictive biomarkers in bladder and kidney cancer to better select patients for curative-intent systemic therapy. Dr Sridhar highlights the recent approval of circulating tumor DNA (ctDNA) in the adjuvant setting for bladder cancer and the ongoing interest in biomarkers such as KIM-1 for kidney cancer. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Srikala Sridhar

New approaches to curing bladder and kidney cancers: where do we stand?
3:07
New approaches to curing bladder and kidney cancers: where do we stand?
Srikala Sridhar • 30 May 2026
JAVELIN Bladder 100: duration of treatment-free interval
3:13
JAVELIN Bladder 100: duration of treatment-free interval
Srikala Sridhar • 8 Jun 2021
Maintenance therapy in urothelial carcinoma
1:02
Maintenance therapy in urothelial carcinoma
Srikala Sridhar • 8 Jun 2021
Immune checkpoint inhibitors in urothelial bladder cancer
2:01
Immune checkpoint inhibitors in urothelial bladder cancer
Srikala Sridhar • 8 Jun 2021

Related Videos

New approaches to curing bladder and kidney cancers: where do we stand?
3:07
New approaches to curing bladder and kidney cancers: where do we stand?
Srikala Sridhar • 30 May 2026
Evaluating the current data for CDK4/6 inhibition in resistant prostate cancer
0:47
Evaluating the current data for CDK4/6 inhibition in resistant prostate cancer
Kevin Zarrabi • 29 May 2026
Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
2:13
Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
Joaquim Bellmunt • 30 May 2026
ctDNA-guided therapy: transforming treatment decisions across tumor types
1:20
ctDNA-guided therapy: transforming treatment decisions across tumor types
Joaquim Bellmunt • 30 May 2026
The content of VJOncology is intended for healthcare professionals